![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Formation in Low-Density Lipoprotein Receptor-Null Mice Fed High Cholesterol
Department of Pharmacology (J.H.L., S.Y.P., C.D.K., W.S.L., B.Y.R., K.W.H.) and Internal Medicine (Y.W.S.), College of Medicine, Pusan National University, Busan, Korea; and Division of Molecular Life Sciences, Ewha Womans University, Seoul, Korea (G.T.O., J.-H.C., J.-G.P.)
This study shows that 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl) butoxy]-3,4-dihydro-2(1H)-quinolinone (cilostazol) suppresses the atherosclerotic lesion formation in the low-density lipoprotein receptor (Ldlr)-null mice. Ldlr-null mice fed a high cholesterol diet showed multiple plaque lesions in the proximal ascending aorta including aortic sinus, accompanied by increased macrophage accumulation with increased expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1). Supplementation of cilostazol (0.2% w/w) in diet significantly decreased the plaque lesions with reduced macrophage accumulation and suppression of VCAM-1 and MCP-1 in situ. Increased superoxide and tumor necrosis factor-
(TNF-
) production were significantly lowered by cilostazol in situ as well as in cultured human umbilical vein endothelial cells (HUVECs). TNF-
-induced increased inhibitory
B
degradation in the cytoplasm and nuclear factor-
B (NF-
B) p65 activation in the nuclei of HUVECs were reversed by cilostazol (1
100 µM) as well as by (E)-3[(4-t-butylphenyl)sulfonyl]-2-propenenitrile (BAY 11-7085) (10 µM), suggesting that cilostazol strongly inhibits NF-
B activation and p65 translocation into the nuclei. Furthermore, in gel shift and DNA-binding assay, cilostazol inhibited NF-
B/DNA complex and nuclear DNA-binding activity of the NF-
B in the nuclear extracts of the RAW 264.7 cells. Taken together, it is suggested that the anti-atherogenic effect of cilostazol in cholesterol-fed Ldlr-null mice is ascribed to its property to suppress superoxide and TNF-
formation, and thereby reducing NF-
B activation/transcription, VCAM-1/MCP-1 expressions, and monocyte recruitments.
Address correspondence to: Dr. Ki Whan Hong, Department of Pharmacology, College of Medicine, Pusan National University, Ami-Dong 1-Ga, Seo-Gu, Busan 602-739, Korea. E-mail: kwhong{at}pusan.ac.kr
This article has been cited by other articles:
![]() |
M. A. Punchard, A. O. Pozzi, T. P. de Prada, M. T. Coronado, P. Gonzalez, and P. Fantidis Letter to the Editor: Monocyte cAMP Content Is Decreased in Patients With Stable Angina Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 436 - 437. [Full Text] [PDF] |
||||
![]() |
L. Gao, F. Wang, B. Wang, B. Gong, J. Zhang, X. Zhang, and J. Zhao Cilostazol Protects Diabetic Rats from Vascular Inflammation via Nuclear Factor-{kappa}B-Dependent Down-Regulation of Vascular Cell Adhesion Molecule-1 Expression J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 53 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Park, J. H. Lee, C. D. Kim, W. S. Lee, W. S. Park, J. Han, Y.-G. Kwak, K. Y. Kim, and K. W. Hong Cilostazol Suppresses Superoxide Production and Expression of Adhesion Molecules in Human Endothelial Cells via Mediation of cAMP-Dependent Protein Kinase-Mediated Maxi-K Channel Activation J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1238 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Matsumoto, T. Kobayashi, K. Wakabayashi, and K. Kamata Cilostazol improves endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from diabetic rats Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H1933 - H1940. [Abstract] [Full Text] [PDF] |
||||